Resultados de procura - Chongqing Tan

  • Mostrando 1 - 5 Resultados de 5
Limitar resultados
  1. 1
    Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

    Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China por Qiao Liu, Zhen Zhou, Xiaohui Zeng, Chongqing Tan

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

    First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis... por Xiaomin Wan, Xia Luo, Chongqing Tan, Xiaohui Zeng, Yucong Zhang, Liubao Peng

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer

    A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Canc... por Siying Wang, Liubao Peng, Jianhe Li, Xiaohui Zeng, Lihui Ouyang, Chongqing Tan, Qiong Lu

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

    Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis por Qiao Liu, Xia Luo, Liubao Peng, Lidan Yi, Xiaomin Wan, Xiaohui Zeng, Chongqing Tan

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

    Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Can... por Chongqing, Tan, Sini, Li, Xiaohui, Zeng, Liubao, Peng, Ye, Peng, Shuxia, Qin, Liting, Wang, Meiyu, Wu, Xiaomin, Wan

    Publicado 2021
    Ligazón do recurso Ligazón do recurso Ligazón do recurso
    Text
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: